**Name of journal: World Journal of Orthopedics**

**ESPS Manuscript NO: 8563**

**Columns: TOPIC HIGHLIGHT**

WJO 5th Anniversary Special Issues (10): Rheumatoid arthritis

Hand bone mass in rheumatoid arthritis: A review of the literature

Kilic G *et al*. Hand bone mass in rheumatoid arthritis

Gamze Kilic, Salih Ozgocmen

**Gamze Kilic, Salih Ozgocmen,** Division of Rheumatology, Department of Physical Medicine and Rehabilitation, Erciyes University, School of Medicine, Gevher Nesibe Hospital, 38039 Kayseri, Turkey

**Author contributions:** Kilic G and Ozgocmen S contributed to the collection and analysis of the data, and drafted the manuscript.

**Correspondence to:** **Salih Ozgocmen, MD,** **Professor, Head,** Division of Rheumatology, Department of Physical Medicine and Rehabilitation, Erciyes University, School of Medicine, Gevher Nesibe Hospital, Talas Yolu üzeri, 38039 Kayseri, Turkey. sozgocmen@hotmail.com

**Telephone:** +90-352-2076666-22278

**Received:** December 29, 2013  **Revised:** July 11, 2014

**Accepted:** July 25, 2014

**Published online:**

**Abstract**

Rheumatoid arthritis (RA) is a common chronic inflammatory disease and periarticular osteoporosis or osteopenia of the inflammed hand joints is an early feature of RA. Quantitative measurement of hand bone loss may be an outcome measure for the detection of joint destruction and disease progression in early RA. This systematic review examined the published literature reporting hand bone mass in patients with RA particularly those using the dual X-ray absorptiometry (DXA) methods. The majority of the studies reported that hand bone loss is associated with disease activity, functional status and radiologic progression in early RA. Quantitative measurement of hand bone mineral density by DXA may be a useful and practical outcome measure in RA and may be predictive for radiographic progression or functional status in patients with early RA.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Rheumatoid arthritis; Hand bone density; Dual-X-ray absorbtiometry; Periarticular; Osteoporosis

**Core tip:** Periarticular osteoporosis or osteopenia affecting the hands is an early characteristic sign of bone damage in rheumatoid arthritis (RA). Dual X-ray absorptiometry (DXA) can be considered as a reproducible, sensitive and non-invasive method to assess hand bone mineral density (BMD) in early RA. Quantitative measurement of hand bone loss by DXA may be a useful and practical outcome measure in RA and may have predictive value to determine radiographic progression or functional status in patients with early RA. Building up a reference populationa to obtain objective and accurate T and Z scores for hand BMD is needed.

Kilic G, Ozgocmen S. Hand bone mass in rheumatoid arthritis: A review of the literature. *World J Orthop* 2014; In press

**INTRODUCTION**

Rheumatoid arthritis (RA) is a severe chronic inflammatory disease and periarticular osteoporosis or osteopenia of inflamed joints is the characteristic feature of the disease[1]. Periarticular bone loss affecting the small joints of the hands is an early feature antedating the bone damage in RA. Hand bone loss occurs earlier than generalized osteoporosis and is associated with subsequent progressive joint destruction in patients with RA[2-4]. Therefore, precise quantification of hand bone loss may predict the severity and progression of joint destruction.

Recently, several imaging methods have been used to assess the peripheral bone mass including plain X-ray[5], quantitative ultrasound (US) [6], peripheral quantitative computed tomography (pQCT)[7], magnetic resonance imaging[8], digital X-ray radiogrammetry[9] and dual X-ray absorptiometry (DXA)[10]. Among them DXA can be considered as an accurate, repeatable and sensitive method to assess hand bone mineral density (BMD) in early RA[11, 12].

Until now, several studies have revealed the correlation of hand BMD with disease activity, functional capacity, radiolographic progression or BMD at other sites in patients with RA[3]. A review of the literature documenting the role of hand DXA in the assessment of progression and joint demage in patients with early RA is necessary. Quantitative measurement of hand bone loss may be an outcome measure for the detection of joint destruction and disease progression in early RA. Therefore this review will examine the published literature assessing hand bone mass in patients with RA particularly those using the DXA methods.

**SEARCH**

Literature was searched for articles assessing hand bone mass in patients with RA. Studies in which hand bone mass has been investigated by using DXA in patients with RA were eligible. Selection criteria consisted of original articles involving humans and published in English. Articles were excluded if they were review articles or meta-analyses and did not measure bone density by using DXA. In our search strategy, the following keywords were used :( rheumatoid arthritis OR RA) AND (hand bone mass OR hand dual X-ray absorptiometry OR hand DXA OR hand bone densitometry OR hand bone mineral density OR hand BMD OR periarticular osteoporosis OR periarticular osteopenia). Literature search was performed in PubMed® and Web of Science ® databases between November 1993 and November 2013. Full texts of the selected articles were independently and systematically screened and data were extracted. For each trial, if applicable, information concerning sample size, study type, demographic characteristics of the patients, interventions, and outcome measures, follow-up data, were collected.

**RESEARCH**

Figure 1 shows the flow chart and the selection process. Thirty four articles fulfilled the inclusion and exclusion criteria. 2131 patients with RA were reported within 18 cross-ectional studies, 12 longitudinal studies and 4 interventional studies. Table 1 shows the study design and characteristics of the studies.

Twelve cross-sectional studies compared patients with RA and controls. Ten studies showed that patients with RA had significantly lower hand BMD compared with matched healthy controls or patients with other rheumatic diseases[13-22]. Similarly, five longitudinal studies reported hand bone loss was higher in patients with RA than matched healthy controls or patients with other rheumatic diseases including spondiloartropathies or undifferentiated arthritis[4, 10, 23-25].

***Hand bone mass and disease duration***

Five longitudinal studies reported that hand bone loss occurred early in the disease duration in patients with RA[4, 10, 23, 24, 26]. A 5-years longitudinal study of hand bone mineral content (BMC) in patients with early RA indicated that the rate of hand bone loss measured by DXA was more pronounced in the first years of disease and then slowed. In this study, the predictors for the bone loss over five years were identified as baseline disease activity, functional status and BMC loss within the first six months[26].

***Hand bone mass and disease activity***

Two cross-sectional[3, 20] and seven longitudinal studies[4, 10, 23, 26-29] reported that hand bone loss was significantly related to disease activity which was assessed by Disease Activity Score 28 (DAS-28), swollen joint count, CRP, Ritchie articular index or early morning stiffness in patients with early RA. However Deodhar *et al*[13] underscored that hand BMC correlated with disease severity but not with disease activity in their pioneering cross-sectional study. Similarly, Njeh *et al*[30] showed that hand bone mineral density (BMD) correlated with functional capacity but not with CRP or ESR. On the other hand, Haugeberg *et al*[4] found that hand bone loss was associated with rheumatoid factor (RF) and mean CRP levels in their longitudinal study.

***Hand bone mass and functional outcome***

Five longitudinal[26, 27, 29, 31, 32] and four cross sectional studies[3, 18, 33, 34] indicated that hand bone loss correlated with functional status and health related quality of life (assessed using the outcome measures including Health Assessment Questionnaire (HAQ) scores, Short Form 36 (SF-36), hand function, grip strength or pinch strength) in the early RA. However, 2 longitudinal studies failed to show significant association between hand bone loss and functional status[4, 35].

***Hand bone mass and radiographic joint damage***

Two cross-sectional studies have revealed a significant correlation between BMC of the hand and radiographic joint damage[13, 18]. Two longitudinal studies have assessed the association between hand BMD and radiographic joint damage[27, 36]. Haugeberg *et al*[36] showed that measurement of hand BMD by DXA was more sensitive than conventional radiographic scores for detecting early damage in patients with RA. Four longitudinal studies have identified the value of hand bone loss as a predictor for long term radiographic damage. A longitudinal study of 50 patients with early RA (whose hand BMD was measured at baseline, 6 and 12 mo) indicated that baseline value of hand BMD was associated with radiographic scores at 12 mo[27]. Another longitudinal study consisting 64 patients with RA confirmed the predictive value of hand BMD loss in the first year for the subsequent radiographic progression (6.4 year follow up)[35]. A longitudinal study by Black *et al*[37] showed hand BMD loss in the first 6 mo might be a predictor for erosions at 12 mo. Similarly Berglin *et al*[31] found significant correlation between hand bone loss and radiologic progression over 24 mo follow up in patients with early RA. On the other hand, two studies failed to show significant correlation between hand BMC loss and radiographic joint damage[25, 26].

***The effect of therapeutic agents on hand bone mass***

Two studies have reported that anti-tumour necrosis factor (anti-TNF) treatment did not have a significant effect on hand bone loss[32, 38], however reduced the bone loss at the hip[32]. Szenpetery *et al*[32] reported that a course of 3-years anti-TNF treatment resulted increase in periarticular BMD at the proximal interphalangeal (PIP) joints but not at the metacarpophalangeal (MCP) joints in patients with RA and psoriatic arthritis (PsA). A study by Haugeberg *et al*[29] revealed that intra-articular corticosteroid injection therapy (IAST) protected the inflamed joints against bone loss which was more pronounced in the MCP periarticular regions. A study by Deodhar *et al*[39] evaluated the effect of denosumab (a fully human monoclonal antibody against receptor activator of nuclear factor-kappaB ligand (RANKL)) on hand BMD and its correlation with erosion scores. Fifty-six patients with RA were randomly assigned to receive either placebo or one of two doses of denosumab (60 mg or 180 mg) every six months for one year. At 12 mo, mean hand BMD increased from baseline in both denosumab groups and decreased progression of bone erosions.

***Hand bone mass and bone turnover markers***

Szentpetery *et al*[32] reported that baseline hand BMD inversely associated with bone turnover markers including bone-specific alkaline phosphatase (bone ALP), procollagen type-I N-propeptide (PINP), C-terminal cross-linking telopeptides (CTX-I) and urinary N-terminal cross-linking telopeptide of type-I collagen (NTX-I) in patients with RA. Murphy *et al*[23] found correlation between baseline serum levels of tissue inhibitor of metalloproteinase 1 (TIMP-1) and periarticular bone loss after 12 mo follow-up in patients with early RA. Also the authors suggested that TIMP may be a predictive biologic marker for periarticular bone loss. Daragon *et al*[25] showed that IL-1, IL-10 and TNF-α were not correlated with hand BMD both in patients with RA and other rheumatic disease.

**DISCUSSION**

In RA, bone involvement characterized by focal articular bone loss (erosions), periarticular osteoporosis/osteopenia around inflamed joints and generalized osteoporosis affecting the axial and peripheral skeleton[40]. Periarticular osteoporosis or osteopenia affecting the hands is an early characteristic sign of bone damage and precedes the development of erosions in RA. Periarticular bone loss and erosions were considered as criteria in the revised 1997 American College of Rheumatology (ACR) classification criteria for RA[41]. Later, radiographic changes were excluded in the new 2010 ACR/European League Against Rheumatism classification criteria for RA due to the subjective evaluation of periarticular demineralization in the early stage of disease by conventional radiography[42].

Although pathogenesis of periarticular bone loss remains less clear, studies support that the periarticular bone loss may occur as a result of imbalance in bone remodeling. In RA, subchondral bone marrow and/or synovial inflammation inhibits bone formation by inhibiting wingless signaling pathway and increases bone resorption by stimulating production of bone-resorbing cytokines such as interleukin-1 (IL-1), IL-6, IL-17 and receptor activator of nuclear factor-κB ligand (RANKL)[43, 44].

Dual X-ray absorptiometry measurement of hand BMD can be considered as an accurate, reproducible, sensitive, non-invasive method in early RA[11, 12]. Also it is a well tolerated and fast procedure. It has a small effective radiation dose and good precision value than conventional radiography. Hand BMD measurements by DXA have been suggested as a more sensitive method than radiologic scoring for detecting bone damage in early RA[36]. DXA measurements provide quantitative results those are free of observer bias. On the other hand, there are many pitfalls using DXA on clinical application for measuring periarticular BMD in patients with RA. First, most elderly patients with RA have severe degenerative changes in the hands including Heberden’s and Bouchard’ nodes which may affect the result of hand BMD measurement and cause higher result of BMC. Second, severe hand deformity in RA causes change in hand position which results a wide variation in the hand BMD measurement but not hand BMC[13]. Third, hand bone loss seems to be the result of generalize plus local effect of the disease. Therefore in patients with establish RA, periarticular bone osteoporosis can be difficult to distinguish from generalized osteoporosis by using hand DXA alone. Moreover, it is also important to note the influence of normal age-related bone loss especially in postmenopausal women. Finally, standard deviation (SDs) for hand BMD measurement by DXA is unknown. All of the studies included in this review compared DXA result with small reference populations. Further studies are needed to investigate SDs from the reference population to obtain objective and accurate results in T and Z scores for hand[18].

Several studies support that hand bone loss occur early in the disease process and more rapidly than at the hip and spine[4, 10, 23, 24, 26, 34]. Ten studies have demonstrated that hand bone loss was higher in patients with RA than matched healthy controls and patients with other rheumatic diseases[13-22].

Only a few studies have examined the effect of several therapeutic agents on hand bone loss assessed by DXA in RA. Several studies have showed that anti-TNF drugs used in the treatment of RA reduces both disease activity and radiographic progression[45, 46]. By contrast, limited data exist on the effect of anti-TNF treatment on periarticular bone loss in patients with RA. Two studies have demonstrated that anti-TNF therapy (infliximab) did not have a significant effect on hand bone loss[32, 38], whereas reduced the bone loss in hip[32]. The mechanism of this failure has not been extensively investigated and is still an open question The effect of RANKL blockade with denosumab on hand BMD was examined in the three treatment arms in a study: placebo or one of two doses of denosumab (60 mg or 180 mg). Mean hand BMD increased from baseline and progression of bone erosions decreased in both denosumab groups compared to placebo[39]. In RA, the effect of intra-articular corticosteroid injections into inflamed finger joints on hand bone loss has been investigated in an interventional study comparing methotrexate (MTX) and IAST with MTX treatment for 1-years. The MTX and IAST treated group had lesser loss in periarticular hand BMD in the first 3 mo[29]. These data suggested that suppressing periarticular inflammation with a potent anti-inflammatory medication such as corticosteroid may decrease periarticular inflammation resulting reduced periarticular bone loss.

Several longitudinal studies suggested that early hand bone loss may have predictive value to determine which patients with early RA will develop further radiographic progression or have poor functional status[26, 27, 31, 35, 37]. However, there are contrasting results. The discrepancy between results may be related to different radiological scoring methods, sample size, disease characteristics or therapetic approaches to be used.

**CONCLUSION**

Quantitative measurement of hand bone loss by DXA may be a useful and practical outcome measure in RA and may be predictive for radiographic progression or functional status in patients with early RA.

**REFERENCES**

1 **Hansen M**, Florescu A, Stoltenberg M, Pødenphant J, Pedersen-Zbinden B, Hørslev-Petersen K, Hyldstrup L, Lorenzen I. Bone loss in rheumatoid arthritis. Influence of disease activity, duration of the disease, functional capacity, and corticosteroid treatment. *Scand J Rheumatol* 1996; **25**: 367-376 [PMID: 8996471]

2 **Güler-Yüksel M**, Klarenbeek NB, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, van der Kooij SM, Gerards AH, Ronday HK, Huizinga TW, Dijkmans BA, Allaart CF, Lems WF. Accelerated hand bone mineral density loss is associated with progressive joint damage in hands and feet in recent-onset rheumatoid arthritis. *Arthritis Res Ther* 2010; **12**: R96 [PMID: 20482894 DOI: 10.1186/ar3025]

3 **Devlin J**, Lilley J, Gough A, Huissoon A, Holder R, Reece R, Perkins P, Emery P. Clinical associations of dual-energy X-ray absorptiometry measurement of hand bone mass in rheumatoid arthritis. *Br J Rheumatol* 1996; **35**: 1256-1262 [PMID: 9010053]

4 **Haugeberg G**, Green MJ, Quinn MA, Marzo-Ortega H, Proudman S, Karim Z, Wakefield RJ, Conaghan PG, Stewart S, Emery P. Hand bone loss in early undifferentiated arthritis: evaluating bone mineral density loss before the development of rheumatoid arthritis. *Ann Rheum Dis* 2006; **65**: 736-740 [PMID: 16284095 DOI: 10.1136/ard.2005.043869]

5 **Saville PD**. A quantitative approach to simple radiographic diagnosis of osteoporosis: its application to the osteoporosis of rheumatoid arthritis. *Arthritis Rheum* 1967; **10**: 416-422 [PMID: 6057645]

6 **Röben P**, Barkmann R, Ullrich S, Gause A, Heller M, Glüer CC. Assessment of phalangeal bone loss in patients with rheumatoid arthritis by quantitative ultrasound. *Ann Rheum Dis* 2001; **60**: 670-677 [PMID: 11406521]

7 **Zhu TY**, Griffith JF, Qin L, Hung VW, Fong TN, Kwok AW, Leung PC, Li EK, Tam LS. Bone density and microarchitecture: relationship between hand, peripheral, and axial skeletal sites assessed by HR-pQCT and DXA in rheumatoid arthritis. *Calcif Tissue Int* 2012; **91**: 343-355 [PMID: 22945690 DOI: 10.1007/s00223-012-9644-z]

8 **Ostergaard M**, Hansen M, Stoltenberg M, Gideon P, Klarlund M, Jensen KE, Lorenzen I. Magnetic resonance imaging-determined synovial membrane volume as a marker of disease activity and a predictor of progressive joint destruction in the wrists of patients with rheumatoid arthritis. *Arthritis Rheum* 1999; **42**: 918-929 [PMID: 10323447 DOI: 10.1002/1529-0131(199905)42: 5<918: : AID-ANR10>3.0.CO; 2-2]

9 **Böttcher J**, Malich A, Pfeil A, Petrovitch A, Lehmann G, Heyne JP, Hein G, Kaiser WA. Potential clinical relevance of digital radiogrammetry for quantification of periarticular bone demineralization in patients suffering from rheumatoid arthritis depending on severity and compared with DXA. *Eur Radiol* 2004; **14**: 631-637 [PMID: 14600776 DOI: 10.1007/s00330-003-2087-1]

10 **Deodhar AA**, Brabyn J, Jones PW, Davis MJ, Woolf AD. Longitudinal study of hand bone densitometry in rheumatoid arthritis. *Arthritis Rheum* 1995; **38**: 1204-1210 [PMID: 7575713]

11 **Fouque-Aubert A**, Chapurlat R, Miossec P, Delmas PD. A comparative review of the different techniques to assess hand bone damage in rheumatoid arthritis. *Joint Bone Spine* 2010; **77**: 212-217 [PMID: 20381399 DOI: 10.1016/j.jbspin.2009.08.009]

12 **Njeh CF**, Genant HK. Bone loss. Quantitative imaging techniques for assessing bone mass in rheumatoid arthritis. *Arthritis Res* 2000; **2**: 446-450 [PMID: 11094457 DOI: 10.1186/ar126]

13 **Deodhar AA**, Brabyn J, Jones PW, Davis MJ, Woolf AD. Measurement of hand bone mineral content by dual energy x-ray absorptiometry: development of the method, and its application in normal volunteers and in patients with rheumatoid arthritis. *Ann Rheum Dis* 1994; **53**: 685-690 [PMID: 7979583]

14 **Alenfeld FE**, Diessel E, Brezger M, Sieper J, Felsenberg D, Braun J. Detailed analyses of periarticular osteoporosis in rheumatoid arthritis. *Osteoporos Int* 2000; **11**: 400-407 [PMID: 10912841]

15 **Castañeda S**, González-Alvaro I, Rodríguez-Salvanés F, Quintana ML, Laffon A, García-Vadillo JA. Reproducibility of metacarpophalangeal bone mass measurements obtained by dual-energy X-ray absorptiometry in healthy volunteers and patients with early arthritis. *J Clin Densitom* 2007; **10**: 298-305 [PMID: 17574466 DOI: 10.1016/j.jocd.2007.04.003]

16 **Alves C**, Colin EM, van Oort WJ, Sluimer JP, Hazes JM, Luime JJ. Periarticular osteoporosis: a useful feature in the diagnosis of early rheumatoid arthritis? Reliability and validity in a cross-sectional diagnostic study using dual-energy X-ray absorptiometry. *Rheumatology (Oxford)* 2011; **50**: 2257-2263 [PMID: 21990370 DOI: 10.1093/rheumatology/ker298]

17 **Moon SJ**, Ahn IE, Kwok SK, Park KS, Min JK, Park SH, Kim HY, Ju JH. Periarticular osteoporosis is a prominent feature in early rheumatoid arthritis: estimation using shaft to periarticular bone mineral density ratio. *J Korean Med Sci* 2013; **28**: 287-294 [PMID: 23399828 DOI: 10.3346/jkms.2013.28.2.287]

18 **Ardicoglu O**, Ozgocmen S, Kamanli A, Pekkutucu I. Relationship between bone mineral density and radiologic scores of hands in rheumatoid arthritis. *J Clin Densitom* 2001; **4**: 263-269 [PMID: 11740068]

19 **Florescu A**, Pødenphant J, Thamsborg G, Hansen M, Leffers AM, Andersen V. Distal metacarpal bone mineral density by dual energy X-ray absorptiometry (DEXA) scan. Methodological investigation and application in rheumatoid arthritis. *Clin Exp Rheumatol* 1993; **11**: 635-638 [PMID: 8299255]

20 **Harrison BJ**, Hutchinson CE, Adams J, Bruce IN, Herrick AL. Assessing periarticular bone mineral density in patients with early psoriatic arthritis or rheumatoid arthritis. *Ann Rheum Dis* 2002; **61**: 1007-1011 [PMID: 12379525]

21 **Franck H**, Gottwalt J. Associations with subregional BMD-measurements in patients with rheumatoid arthritis. *Rheumatol Int* 2008; **29**: 47-51 [PMID: 18597090 DOI: 10.1007/s00296-008-0638-0]

22 **Ozgocmen S**, Karaoglan B, Kocakoc E, Ardicoglu O, Yorgancioglu ZR. Correlation of hand bone mineral density with the metacarpal cortical index and carpo: metacarpal ratio in patients with rheumatoid arthritis. *Yonsei Med J* 1999; **40**: 478-482 [PMID: 10565260]

23 **Murphy E**, Roux-Lombard P, Rooney T, Fitzgerald O, Dayer JM, Bresnihan B. Serum levels of tissue inhibitor of metalloproteinase-1 and periarticular bone loss in early rheumatoid arthritis. *Clin Rheumatol* 2009; **28**: 285-291 [PMID: 19050823 DOI: 10.1007/s10067-008-1037-3]

24 **Jensen T**, Klarlund M, Hansen M, Jensen KE, Pødenphant J, Hansen TM, Skjødt H, Hyldstrup L. Bone loss in unclassified polyarthritis and early rheumatoid arthritis is better detected by digital x ray radiogrammetry than dual x ray absorptiometry: relationship with disease activity and radiographic outcome. *Ann Rheum Dis* 2004; **63**: 15-22 [PMID: 14672886]

25 **Daragon A**, Krzanowska K, Vittecoq O, Ménard JF, Hau I, Jouen-Beades F, Lesage C, Bertho JM, Tron F, Le Loët X. Prospective X-ray densitometry and ultrasonography study of the hand bones of patients with rheumatoid arthritis of recent onset. *Joint Bone Spine* 2001; **68**: 34-42 [PMID: 11235778]

26 **Deodhar AA**, Brabyn J, Pande I, Scott DL, Woolf AD. Hand bone densitometry in rheumatoid arthritis, a five year longitudinal study: an outcome measure and a prognostic marker. *Ann Rheum Dis* 2003; **62**: 767-770 [PMID: 12860734]

27 **Hill CL**, Schultz CG, Wu R, Chatterton BE, Cleland LG. Measurement of hand bone mineral density in early rheumatoid arthritis using dual energy X-ray absorptiometry. *Int J Rheum Dis* 2010; **13**: 230-234 [PMID: 20704619 DOI: 10.1111/j.1756-185X.2010.01485.x]

28 **Naumann L**, Hermann KG, Huscher D, Lenz K, Burmester GR, Backhaus M, Buttgereit F. Quantification of periarticular demineralization and synovialitis of the hand in rheumatoid arthritis patients. *Osteoporos Int* 2012; **23**: 2671-2679 [PMID: 22349908 DOI: 10.1007/s00198-012-1897-x]

29 **Haugeberg G**, Morton S, Emery P, Conaghan PG. Effect of intra-articular corticosteroid injections and inflammation on periarticular and generalised bone loss in early rheumatoid arthritis. *Ann Rheum Dis* 2011; **70**: 184-187 [PMID: 20805297 DOI: 10.1136/ard.2009.128124]

30 **Njeh CF**, Boivin CM, Gough A, Hans D, Srivastav SK, Bulmer N, Devlin J, Emery P. Evaluation of finger ultrasound in the assessment of bone status with application of rheumatoid arthritis. *Osteoporos Int* 1999; **9**: 82-90 [PMID: 10367033]

31 **Berglin E**, Lorentzon R, Nordmark L, Nilsson-Sojka B, Rantapää Dahlqvist S. Predictors of radiological progression and changes in hand bone density in early rheumatoid arthritis. *Rheumatology (Oxford)* 2003; **42**: 268-275 [PMID: 12595621]

32 **Szentpetery A**, McKenna MJ, Murray BF, Ng CT, Brady JJ, Morrin M, Radovits B, Veale DJ, Fitzgerald O. Periarticular bone gain at proximal interphalangeal joints and changes in bone turnover markers in response to tumor necrosis factor inhibitors in rheumatoid and psoriatic arthritis. *J Rheumatol* 2013; **40**: 653-662 [PMID: 23457381 DOI: 10.3899/jrheum.120397]

33 **Dogu B**, Kuran B, Yilmaz F, Usen A, Sirzai H. Is hand bone mineral density a marker for hand function in patients with established rheumatoid arthritis? The correlation among bone mineral density of the hand, radiological findings and hand function. *Clin Rheumatol* 2013; **32**: 1177-1183 [PMID: 23588882 DOI: 10.1007/s10067-013-2253-z]

34 **Peel NF**, Spittlehouse AJ, Bax DE, Eastell R. Bone mineral density of the hand in rheumatoid arthritis. *Arthritis Rheum* 1994; **37**: 983-991 [PMID: 8024625]

35 **Bejarano V**, Hensor E, Green M, Haugeberg G, Brown AK, Buch MH, Emery P, Conaghan PG. Relationship between early bone mineral density changes and long-term function and radiographic progression in rheumatoid arthritis. *Arthritis Care Res (Hoboken)* 2012; **64**: 66-70 [PMID: 21770041 DOI: 10.1002/acr.20553]

36 **Haugeberg G**, Green MJ, Conaghan PG, Quinn M, Wakefield R, Proudman SM, Stewart S, Hensor E, Emery P. Hand bone densitometry: a more sensitive standard for the assessment of early bone damage in rheumatoid arthritis. *Ann Rheum Dis* 2007; **66**: 1513-1517 [PMID: 17491097 DOI: 10.1136/ard.2006.067652]

37 **Black RJ**, Spargo L, Schultz C, Chatterton B, Cleland L, Lester S, Hill CL, Proudman SM. Decline in hand bone mineral density indicates increased risk of erosive change in early rheumatoid arthritis. *Arthritis Care Res (Hoboken)* 2014; **66**: 515-522 [PMID: 24127342 DOI: 10.1002/acr.22199]

38 **Haugeberg G**, Conaghan PG, Quinn M, Emery P. Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study. *Ann Rheum Dis* 2009; **68**: 1898-1901 [PMID: 19386610 DOI: 10.1136/ard.2008.106484]

39 **Deodhar A**, Dore RK, Mandel D, Schechtman J, Shergy W, Trapp R, Ory PA, Peterfy CG, Fuerst T, Wang H, Zhou L, Tsuji W, Newmark R. Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients. *Arthritis Care Res (Hoboken)* 2010; **62**: 569-574 [PMID: 20391513 DOI: 10.1002/acr.20004]

40 **Walsh NC**, Crotti TN, Goldring SR, Gravallese EM. Rheumatic diseases: the effects of inflammation on bone. *Immunol Rev* 2005; **208**: 228-251 [PMID: 16313352 DOI: 10.1111/j.0105-2896.2005.00338.x]

41 **Arnett FC**, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 1988; **31**: 315-324 [PMID: 3358796]

42 **Aletaha D**, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovský J, Wolfe F, Hawker G. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Arthritis Rheum* 2010; **62**: 2569-2581 [PMID: 20872595 DOI: 10.1002/art.27584]

43 **Deal C**. Bone loss in rheumatoid arthritis: systemic, periarticular, and focal. *Curr Rheumatol Rep* 2012; **14**: 231-237 [PMID: 22527950 DOI: 10.1007/s11926-012-0253-7]

44 **Goldring SR**. Periarticular bone changes in rheumatoid arthritis: pathophysiological implications and clinical utility. *Ann Rheum Dis* 2009; **68**: 297-299 [PMID: 19213745 DOI: 10.1136/ard.2008.099408]

45 **Hoff M**, Kvien TK, Kälvesten J, Elden A, Kavanaugh A, Haugeberg G. Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: subanalysis of the PREMIER study. *BMC Musculoskelet Disord* 2011; **12**: 54 [PMID: 21352592 DOI: 10.1186/1471-2474-12-54]

46 **Corrado A**, Neve A, Maruotti N, Cantatore FP. Bone effects of biologic drugs in rheumatoid arthritis. *Clin Dev Immunol* 2013; **2013**: 945945 [PMID: 23864880 DOI: 10.1155/2013/945945]

47 **Ozgocmen S**, Kiris A, Kocakoc E, Ardicoglu O, Kamanli A. Evaluation of metacarpophalangeal joint synovitis in rheumatoid arthritis by power Doppler technique: relationship between synovial vascularization and periarticular bone mineral density. *Joint Bone Spine* 2004; **71**: 384-388 [PMID: 15474389 DOI: 10.1016/j.jbspin.2003.06.003]

48 **Jensen T**, Hansen M, Jensen KE, Pødenphant J, Hansen TM, Hyldstrup L. Comparison of dual X-ray absorptiometry (DXA), digital X-ray radiogrammetry (DXR), and conventional radiographs in the evaluation of osteoporosis and bone erosions in patients with rheumatoid arthritis. *Scand J Rheumatol* 2005; **34**: 27-33 [PMID: 15903022]

49 **Murphy E**, Bresnihan B, FitzGerald O. Measurement of periarticular bone mineral density in the hands of patients with early inflammatory arthritis using dual energy x-ray absorptiometry. *Clin Rheumatol* 2008; **27**: 763-766 [PMID: 18288445 DOI: 10.1007/s10067-007-0833-5]

**P-Reviewer:** El Maghraoui A, Mori K, Yamaguchi M **S-Editor:** Wen LL

**L-Editor: E-Editor:**

Included based on;

-Cross sectional, longitudinal and interwention studies concerning measurement of hand bone loss by using DXA in patients with RA

-original articles involving humans, published in English

4 interventional studies

12 longitudinal studies

Search terms (rheumatoid arthritis OR RA) AND (hand bone mass OR hand dual x ray absorptiometry OR hand dxa OR hand bone densitometry OR hand bone mineral density OR hand bmd OR periarticular osteoporosis OR periarticular osteopenia)

980 hits on MedLine®

327 hits on Web of Science®

Excluded based on abstract review if:

-the report was a review article, meta-analyses

- did not report patients with RA

- did not measure bone density by DXA

- did not report original data

-the papers were not about adverse events

18 cross sectional studies

**Figure 1 Flow chart.** RA: Rheumatoid arthritis.

**Table 1** **Details of the studies included in the systematic reviews**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Study type** | **Sample size**  **(M/F)** | **Mean/Median Age** | **Disease duration (yr)** | **DXA equipment** | **DXA site** | **Coefficient variation BMD** | **Follow-up duration** | **Outcome** | **Conclusion** |
| Florescu *et al*[19] | CS | RA:10  HSl:10 | 63 | 15.3 | Norland | MC bones (II-V) | 0.9%-3.0% |  | There was a significant correlation between hand BMD and radiographic scoring methods. | Hand BMD measurement may be a useful method for the detection and monitor of disease progression. |
| Peel *et al*[34] | CS | RA:70 F | 64 | 3-45 |  | WH, LS, femoral neck |  |  | Increased decrease in BMD in patients with RA vs controls  Hands:22.7%  Lumbar spine:10.7%  Femoral neck:16.3%  Total body:11.3% | Sgnificant correlation between hand BMD and BMD at other sites. Hand BMD correlated with grip strength and inversely related to ESR in patients with early RA. |
| Deodhar *et al*[13] | CS | RA:56 (22/34)  Controls:95 (46/49) | M:64  F :64 | 9 | Hologic | WH | 1%-3% |  | Mean total hand BMC (grams, M/F)  RA:81.7 /52.3  Controls:90.9/62.2 | Hand BMD correlated with disease severity but not with disease activity |
| Devlin *et al*[3] | CS | RA:202 (61/141) | M:59  F: 53 | M:1.6  F:1.9 | Lunar | LS  Hip  WH | 0.6% |  | Hand BMD correlated with disease activity, functional capacity, lumbar and hip BMD. | Hand bone loss is potentially an outcome measure |
| Njeh at al.[30] | CS | RA :51 F  Patients with osteopenia: 44 F  HC:52 F | Mean age  57.5 |  | Lunar DPX-L | LS, hip, WH |  |  | Mean Hand BMD (g/cm2)  in patients with RA:0.415 | Hand BMD was correlated with phalangeal US and hand functions but not CRP or ESR |
| Ozgocmen *et al*[22] | CS | RA: 30 F  HC: 29 F | 45.5 |  | Lunar | WH  II MC  LS  Hip | - |  | CI and C:MC ratio correlated with II.MC midshaft and hand BMD. | CI may predict cortical bone mass of the hand.  C:MC ratio is a useful method for evaluating progression of wrist involvement. |
| Alenfeld *et al*[14] | CS | RA: 41 (18/23)  HC: 103 (35/68) | 54 | F: 2.1  M: 2 | Lunar | WH  Subcondral ROI | WH:0.9 subcondral region: 2.7%- 3.2% |  | Hand bone loss in the subregional regions is higher than total hand BMD | In early RA periarticular osteoporosis may be better assessed using detailed hand scan analyses |
| Ardicoglu *et al*[18] | CS | RA:49 (9/40)  HS:34 (5/29) | 49.1 | 5 | Lunar | LS  Hip  WH |  |  | Hand BMD correlated with disease duration, CRP and radiographic scores | Hand BMD by DXA is a useful pratical and reproducible method |
| Harrison *et al*[20] | CS | RA:17 (4/13)  PsA:15 (9/6) | RA:51  PsA:53 | RA:31  PsA:27 | Hologic | MCP, PIP, DIP joints | 3.4%-6.6% |  | Periarticular BMD was significantly lower in patient with RA than PsA.  Periarticular BMD correlated with the number of swollen, tender joints in RA. | Periarticular osteoporosis is associated with joint inflammation in RA but not PsA |
| Ozgocmen *et al*[47] | CS | RA: 15 F  HS: 3 F | 48.5 | 6.8 | Lunar | WH, MCP | - |  | Flow patterns correlated with intra-articular bone and cartilage destruction | PDUS is a useful method for monitoring disease activity and measurement of therapeutic response. |
| Jensen at al.[48] | CS | RA:11 female | 53 |  | Hologic | MC bones,  forearm | 0.65%-0.83% |  | There was a significant association between DXA-BMD and DXR -BMD | Periarticular bone loss can be detected better and earlier with DXR than DXA in patients with RA |
| Castaneda *et al*[15] | CS | EA:22(2/20)  HC:16 (3/13) | EA:48.4  HC:49.2 | 0.4 | Hologic | WH  MCP | MCP: 1.3% -0.7% WH:1.4 %-0.9% |  | Whole hand BMD: (g/cm2)  HC:0.355EA:0.349  MCP BMD: (g/cm2)  HS:0.295, EA:0.285 | Measurement of BMD at MCP joints may be a useful method to assess the diagnosis or prognosis in patients with EA |
| Franck *et al*[21] | CS | RA:421 (64/357)  HC:98 (31/67) | M:56.11  F:58.4 | M:4.8.  F:4.8 | Hologic | LS, hip, forearm,WH, MCP II-III | Subregional scans:  0.9%-1.4% for short term, 1.5%-2.3% for mid-term |  | There was a significant correlation between WH BMD and its subregions, hip and forearm. Subregional BMD was correlated with CRP, bone resorption markers and grip strength. | Measurement of hand and subregional BMD by DXA is accurate and reproducible method in RA |
| Murphy *et al*[49] | CS | RA:4  SpA: 3 | 36.7 | 1.25 | Hologic | MCP/ PIP | 0.73%-  0.78% |  | The precision of MCP joints was greater than PIP joints | DXA can be used as a reliable measure for periarticular BMD |
| Alves *et al*[16] | CS | Established RA: 25  EA: 25  HS: 37 | Established RA: 53  Early arthritis: 52 |  | Lunar | WH, LS, hip, MCP and/or PIP joints mid MC to mid-phalangeal | 0.45%-1.07% |  | Mean BMD of five ROI:  Established RA: 0.321 to 0.372  Early arthritis: 0.321 to 0.382  HC:0.342 to 0.401  Mean BMD of whole hand:  Established RA: 0.387  Early arthritis: 0.392  HC:0.420 | Measurement of periarticular BMD is not a useful tool to discriminate patients with early RA from HC |
| Tracy *et al*[7] | CS | RA: 100 F | 53.4 | 9.1 | Hologic | LS , hip, ultradistal  radius |  |  | BMD assessed by HR-pQCT significantly correlated wth BMD at the peripheral and central skeleton | HR-pQCT is a useful method for evaluating periarticular bone loss at both cortical and trabecular bone. |
| Moon *et al*[17] | CS | RA:45  HC:106 | 47.5 |  | Lunar | Shaft and periarticular region of PIP, LS, hip |  |  | The ratio of shaft to periarticular BMD was higher in patients with RA | DXA assisted localized quantification and BMD ratio calculations are useful for assessing periarticular osteoporosis in early RA. |
| Dogu *et al*[33] | CS | RA:83 | 52.9 | 6.99 | Lunar | WH |  |  | Hand BMD was correlated with HGS, TTP, radiologic erosions but not DHI. | HGS and TTP were most effective indicator of hand function |
| Deodhar *et al*[10] | LS | RA:81 (33/48)  HC:95 (46/49) | Early RA: M:53, F: 55  Late RA M:65.5,  F: (63) | Early RA:0.8 Late RA:9 | Hologic | WH | - | 1 | After 1 y hand bone loss  Early RA: M:3.25%,F: 1.46% Late RA, no significant loss of hand BMD. | Hand bone loss was highest in patients with early RA and correlated with disease activity. |
| Daragon *et al*[25] | LS | Early RA:15(6/9) Other rheunatic diseases: 15(7/8) | Early RA:42.7  Other rheumatoid diseases:48.8 | 0.4 | Hologic | WH |  | 1 | There was no significant correlation between hand bone loss and clinical, radiologic and biological parametres except for IFN alfa | Hand BMD by DXA may be useful tool for the early classification of inflammatory disease. |
| Deodhar *et al*[26] | LS | Early RA:40 | - | <2 | Hologic | WH | 2.3% | 5 | Percent change in BMD after  1 yr: -5.5, 2 yr:-7.5, 3yr:-9.8, 4 yr:-9.9, and 5.yr: -10 | Early loss in hand BMD (in the first six months) may be a prognostic marker for disease activity, functional status or poor functional outcome. |
| Berglin *et al*[31]. | LS | RA:43(13/30) | M~:56  F:~49 | 0.6 | Lunar | WH |  | 2 | Hand bone loss correlated with radiographic progression | Hand bone loss and radiographic progression were retarded by early treatment |
| Jensen *et al*[24] | LS | RA:51 (10/41)  Unclassified polyarthritis.21 (3/18) | RA:54  Unclassifiesd polyarthritis:39 | 0.3 | Norland | MCP, forearm |  | 2 | Hand BMD decreased only in patients with RA and associated with disease activity. | DXR is better than DXA for detecting and monitoring periarticular osteoporosis of the MC bones. |
| Haugeberg [4] *et al* | LS | Undifferentiated hand arthritis: 74 (9/65) | 65 | 0.5 | Lunar | LS  Hip  WH | 1.07% | 1 | At the 1 year follow-up, hand BMD loss;  RA : -4.27  Inflammatory non-rheumatoid group: -0.49  Non-inflammatory group:-0.87 | Hand DXA may be useful for determining the risk of progressive disease in RA |
|  |  |  |  |  |  |  |  |  |  |  |
| Haugeberg *et al*[36] | LS | RA:79 (32/47) | 49.7 | 0.7 | Lunar | WH  LS  Hip |  | 0.9 | Mean hand BMD loss 2.5% at 24 wk, 2.6% at 48 wk | Hand DXA is more sensitive than radiology can be used as outcome measure in early RA |
| Murphy *et al*[23] | LS | RA: 20(8/12)  SpA:18(11/7) | RA:37, SpA:33 | RA: 0.4  SpA:0.4 | Hologic | MCP/PIP  LS |  | 1 | Periarticular bone loss correlated with radiographic damage, disease activity and baseline TIMP-1 level | TIMP-1 may be use as a biomarker of periarticular bone loss in early RA. |
| Hill *et al*[27] | LS | RA:50 (12/38)  Control: 30 | 57 | 0.75 | Lunar | WH, lumbar spine, hip | 1.1% | 1 | Hand BMD correlated with baseline CRP and radiographic score in RA | Hand BMD using DEXA is a safe, reproducible procedure .It may predict radiologic progression and disease activity. |
| Bejarano *et al*[35] | LS | RA: 64 (27/37) | 54.1 | 0.5 |  | WH, LS, hip |  | 6.4 y | Follow-up change in hand BMD, -0.034 | First year hand BMD loss was not associated with function or quality of life status but not long-term radiographic progression. |
| Naumann [28] *et al* | LS | Early RA:17 (4/13)  Established RA: 35 (8/27) | Early RA:55,  Established RA with moderate disease activity:58  Established RA with high disease activity:53.5 | Early RA:0.2 | Lunar | WH, MCP / PIP, wrist, LS hip | Wrist:0.75  WH :0.78 | 1 | There was a negative correlation between hand BMD and MCP joint synovitis in patients with high diasease activity. The best precision values of BMD were found for the wrist. | Hand BMD measurement by DXA is highly reproducible method in patients with RA. |
| Black *et al*[37] | LS | RA:106 (29/77) | 57 | 0.3 | Lunar | WH |  | 1 | Lower hand BMD was associated with higher erosion scores. | Hand BMD loss in the first 6 months can predict early erosive change in patients with early RA. |
| Haueberg *et al*[38] | IS | RA: 20 (7/13)  IFX+MTX:10  Placebo + MTX:10 | 52.2 | <1 | Lunar | WH, LS, hip |  | 1 | BMD (gr/cm2)  IFX treated group: WH:0.42, spine:1.14, T hip:1.04, F neck:1.03  Placebo:WH:0.43, spine:1.28,T hip:1.06, F neck:1.01 | In the IFX treated group hand bone loss arrested at the hip but not at the hand and lumbar spine |
| Deodhar *et al*[39] | IS | Pacebo: 13  Denosumab 60 mg treated group:21 (7/14)  Denasumab 120 mg treated group:22 (5/17) | Pacebo: 55.2  Denosumab 60 mg treated group:57.7  Denasumab 120 mg treated group:58.7 | Pacebo: 10.3  Denosumab 60 mg treated group:12.6  Denasumab 120 mg treated group:15.8 | Lunar | WH |  | 1 | Mean change in hand BMD at 6/ 12 months ( %);  denosumab 60 mg: 0.8/1  denosumab 180 mg: 2/ 2.5  placebo:-1.2/- 2 | Denasumab increased hand BMD and decreased progression of bone erosion in RA |
| Haugeberg [29] *et al* | IS | MTX group:19 (10/9)  MTX+IAST:21(8/13) | MTX group:56.2  MTX+IAST:53.3 | MTX group:0.5  MTX+IAST:0.4 | Lunar | WH, MCP, hip, LS |  | 1 | In the first 3 months, hand bone loss was lower in MTX+IAST treated group than MTX treated group. Hand bone loss associated disease activity, hand function and MRI synovitis score | IAST may protect against periarticular bone loss in inflamed finger joints in RA. |
| Szentpetery *et al*[32] | IS | RA:35 (11/24)  PsA:27 (12/15) | RA:56  PsA:44 | RA: 8  PsA: 7 | Hologic | WH, PIP/ MCP, hip, LS |  | 3 | Following anti- TNF therapy  hip BMD decreased but  spine and hand BMD unchanged. Periarticular BMD around PIP joints increased , MCP decreased | Anti TNF therapy increased bone formation without a change in bone resorption |

CS: Crosssectional study; CI: Cortical index; C:MC: Carpo:metacarpal; EA: Early arthritis; DXR: Digital X ray radiogrammetry; DXA: Dual X ray absorptiometry; HR-pQCT: High-resolution peripheral quantitative computed tomography; HGS: Handgrip strength; IAST: Intra-articular corticosteroid; HC: Healthy controls; IS: Interventional study; LS: Longitudinal study; PsA: Psoriatic arthritis; ROI: Region of interest; RA: Rheumatoid arthritis; SpA: Spondiloartropathy; TIMP-1: Tissue inhibitor of metalloproteinases 1; TTP: Three-finger pinch; vBMD: Trabecular volumetric bone mineral density; WH: Whole hand; LS: lumbar spine.